Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M D Mayes

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Annals of the Rheumatic Diseases|September 26, 2007
Development of a provisional core set of response measures for clinical trials of systemic sclerosisD Khanna, D J Lovell, E Giannini, et al.
Arthritis and Rheumatism|April 1, 1997
Racial differences in scleroderma among women in MichiganT J Laing, B W Gillespie, M B Toth, et al.
International Journal of Immunopathology and Pharmacology|June 13, 2013
STAT4 is a genetic risk factor for systemic sclerosis in a Chinese populationL Yi, J C Wang, X J Guo, et al.
The Journal of Rheumatology|March 7, 1998
Safety and pharmacokinetics of recombinant human relaxin in systemic sclerosisJ R Seibold, P J Clements, D E Furst, et al.
Annals of the Rheumatic Diseases|May 9, 2007
Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosisPhilip J Clements, Michael D Roth, Robert Elashoff, et al.
Rheumatology (Oxford, England)|June 27, 2001
Effects of the American College of Rheumatology systemic sclerosis trial guidelines on the nature of systemic sclerosis patients entering a clinical trialD E Furst, P J Clements, W K Wong, et al.
Annals of Internal Medicine|June 3, 2000
Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trialJ R Seibold, J H Korn, R Simms, et al.
Annals of the Rheumatic Diseases|March 17, 2006
Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine studyD Khanna, D E Furst, R D Hays, et al.
Arthritis and Rheumatism|April 29, 1998
Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind studyF M Wigley, J H Korn, M E Csuka, et al.
Annals of the Rheumatic Diseases|October 10, 2009
BANK1 functional variants are associated with susceptibility to diffuse systemic sclerosis in CaucasiansB Rueda, P Gourh, J Broen, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Annals of the Rheumatic Diseases|September 26, 2007
Development of a provisional core set of response measures for clinical trials of systemic sclerosisD Khanna, D J Lovell, E Giannini, et al.
Arthritis and Rheumatism|April 1, 1997
Racial differences in scleroderma among women in MichiganT J Laing, B W Gillespie, M B Toth, et al.
International Journal of Immunopathology and Pharmacology|June 13, 2013
STAT4 is a genetic risk factor for systemic sclerosis in a Chinese populationL Yi, J C Wang, X J Guo, et al.
The Journal of Rheumatology|March 7, 1998
Safety and pharmacokinetics of recombinant human relaxin in systemic sclerosisJ R Seibold, P J Clements, D E Furst, et al.
Annals of the Rheumatic Diseases|May 9, 2007
Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosisPhilip J Clements, Michael D Roth, Robert Elashoff, et al.
Rheumatology (Oxford, England)|June 27, 2001
Effects of the American College of Rheumatology systemic sclerosis trial guidelines on the nature of systemic sclerosis patients entering a clinical trialD E Furst, P J Clements, W K Wong, et al.
Annals of Internal Medicine|June 3, 2000
Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trialJ R Seibold, J H Korn, R Simms, et al.
Annals of the Rheumatic Diseases|March 17, 2006
Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine studyD Khanna, D E Furst, R D Hays, et al.
Arthritis and Rheumatism|April 29, 1998
Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind studyF M Wigley, J H Korn, M E Csuka, et al.
Annals of the Rheumatic Diseases|October 10, 2009
BANK1 functional variants are associated with susceptibility to diffuse systemic sclerosis in CaucasiansB Rueda, P Gourh, J Broen, et al.
Pageof 6